Vir Biotechnology, Inc. (VIR) stock
VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/3021% below fair value
$9.96−2.16 (-17.82%)
Close on Nov 13, 2026Market cap $1.69BP/E –Yield –
Vir Biotechnology r&d expenses
Research and development expenses are spending on new products and technology.
Vir Biotechnology's R&D Expenses for the twelve months ending Sep 30, 2026 was $412.59M, down 12.9% year over year. For fiscal 2025 it was $455.97M, down 10.0% from the year before. The highest annual figure on record is $579.72M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $455.97M | -10.0% |
| FY2024 | Dec 31, 2024 | $506.50M | -12.6% |
| FY2023 | Dec 31, 2023 | $579.72M | +22.1% |
| FY2022 | Dec 31, 2022 | $474.65M | +5.9% |
| FY2021 | Dec 31, 2021 | $448.01M | +48.1% |
| FY2020 | Dec 31, 2020 | $302.41M | +103.7% |
| FY2019 | Dec 31, 2019 | $148.47M | +48.1% |
| FY2018 | Dec 31, 2018 | $100.23M | +60.3% |
| FY2017 | Dec 31, 2017 | $62.51M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $80.04M | -47.2% |
| Q2 FY2026 | Jun 30, 2026 | $135.28M | +38.7% |
| Q1 FY2026 | Mar 31, 2026 | $108.92M | -8.2% |
| Q4 FY2025 | Dec 31, 2025 | $88.35M | -16.7% |
| Q3 FY2025 | Sep 30, 2025 | $151.46M | -22.4% |
| Q2 FY2025 | Jun 30, 2025 | $97.51M | -7.2% |
| Q1 FY2025 | Mar 31, 2025 | $118.65M | +18.5% |
| Q4 FY2024 | Dec 31, 2024 | $106.08M | -2.6% |
| Q3 FY2024 | Sep 30, 2024 | $195.18M | +34.6% |
| Q2 FY2024 | Jun 30, 2024 | $105.11M | -37.5% |
| Q1 FY2024 | Mar 31, 2024 | $100.13M | -36.5% |
| Q4 FY2023 | Dec 31, 2023 | $108.97M | -29.8% |
| Q3 FY2023 | Sep 30, 2023 | $145.03M | +27.0% |
| Q2 FY2023 | Jun 30, 2023 | $168.08M | +46.1% |
| Q1 FY2023 | Mar 31, 2023 | $157.64M | +74.7% |
| Q4 FY2022 | Dec 31, 2022 | $155.17M | +20.9% |
| Q3 FY2022 | Sep 30, 2022 | $114.17M | +15.7% |
| Q2 FY2022 | Jun 30, 2022 | $115.08M | +33.6% |
| Q1 FY2022 | Mar 31, 2022 | $90.23M | -33.1% |
| Q4 FY2021 | Dec 31, 2021 | $128.34M | +47.4% |
| Q3 FY2021 | Sep 30, 2021 | $98.67M | +39.6% |
| Q2 FY2021 | Jun 30, 2021 | $86.13M | +8.1% |
| Q1 FY2021 | Mar 31, 2021 | $134.87M | +107.6% |
| Q4 FY2020 | Dec 31, 2020 | $87.10M | +64.5% |
| Q3 FY2020 | Sep 30, 2020 | $70.68M | +77.3% |
| Q2 FY2020 | Jun 30, 2020 | $79.65M | +167.2% |
| Q1 FY2020 | Mar 31, 2020 | $64.98M | +151.2% |
| Q4 FY2019 | Dec 31, 2019 | $52.93M | +140.9% |
| Q3 FY2019 | Sep 30, 2019 | $39.86M | +33.6% |
| Q2 FY2019 | Jun 30, 2019 | $29.81M | – |
| Q1 FY2019 | Mar 31, 2019 | $25.87M | – |
| Q4 FY2018 | Dec 31, 2018 | $21.97M | – |
| Q3 FY2018 | Sep 30, 2018 | $29.84M | – |
See a number that looks wrong?